Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of HALO's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Jun 14, 2023
Questions asked 10 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 10 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 4 of 4 closing letter

Half the closed reviews took 71 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-06-14 to 2023-07-21 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2023-07-21
Legal and contingenciesDerivatives and hedgingDebt
Notes to Consolidated Financial Statements
SEC asked
Long-Term Debt, Net, page F-30 1. We note that each of your 2024, 2027 and 2028 Convertible Notes are convertible at the option of the holder only in certain circumstances. Please explain to us how you evaluated these instruments to determine whether the conversion features were required to be bifurcated and accounted for as a derivative under ASC 815.
Rest of the question

In your response, specifically address whether each conversion option contingency meets the definition of a derivative and, if so, whether it qualifies for the scope exception for contracts involving an entity's own equity as set forth in ASC 815-10-15-74(a). Please also revise your accounting policy disclosure accordingly in your future filings.

HALO answered
The Company assessed the embedded conversion features to determine if bifurcation from the notes and derivative accounting pursuant to ASC 815-15-25-1 is required. As part of the analysis, the embedded conversion features were assessed to determine if they meet the definition of a derivative and qualify for a derivative scope exception.

The conversion features for each of our 2024, 2027 & 2028 convertible notes include similar contingent conversion features related to free convertibility periods, common stock price triggers, Company’s redemption, certain corporate events and make-whole
Rest of the answer

provisions upon a fundamental change in control. Because of the similarities of each of the notes’ conversion features, the analyses of each notes’ conversion features is the same for the purpose of the response and are therefore addressed as a whole.

First, we followed ASC 815-10-15-83 to determine whether a conversion option meets the definition of a derivative. Based on that guidance, the definition of derivative requires certain contractual characteristics including an underlying, notional or payment provision, no initial net investment and net settlement. The underlying for the conversion features is the Company’s common stock and the notional amount is the specified shares of the Company’s common stock. Based on ASC 815-15-25-1(C), the embedded conversion features of the Company’s convertible notes will not be considered to have an initial investment. Per ASC 815-10-15-119 through 15-121, publicly traded shares are considered readily convertible to cash and meets the net settlement criteria. Based on the above analysis, we determined that the conversion option meets the definition of a derivative.

ASC 815-10-15-74(a) also states that if an embedded conversion option meets the definition of a derivative, a reporting entity should assess whether it qualifies for the scope exception for certain contracts involving a reporting entity’s own equity. Per the guidance, a reporting entity shall not consider the following contracts to be derivative instruments:

Contracts issued or held by the reporting entity that are both:

1. Indexed to its own stock

2. Classified in stockholders’ equity in its statement of financial position.

1. Indexed to reporting entity’s common stock - to determine whether the conversion features are indexed to the Company’s common stock, we followed the two-step approach in accordance with ASC 815-40-15-5. The guidance requires the evaluation of an instrument’s or embedded component’s contingent exercise provisions and then the instrument’s embedded component’s settlement provisions.

The conversion features contingencies are not based on an observable market other than our stock price and an observable index other than index calculated by the Company’s operations.

The conversion features contingencies are only impacted by the Company’s stock price and business operations. As such, the conversion feature exercise contingencies do not preclude the conversion features from being deemed indexed to the Company’s own equity. The second step is evaluating whether the settlement provision is consistent with a fixed-for-fixed equity instrument. Although the conversion option contains provisions for adjustments to the conversion rate, the adjustments to the conversion rate are all designed to compensate the holder for changes in the fair value (in certain cases in order to maintain the fair value of the instrument before and after certain events) and the adjustments are all related to the Company’s stock price volatility, expected dividends, or anti-dilutive activities which do not preclude conversion from being deemed index to Company’s own stock (ASC 815-40-15). For instance, the settlement provision for our convertible notes is determined based on the volume-weighted average daily market price (VWAP) and the settlement amount is not always based on a fixed number of shares. However, ASC 815-40-55-38, states that if the only variable that causes the settlement amount to differ from a fixed-for-fixed settlement amount is the daily VWAP of the entity’s common stock, the conversion feature is still deemed indexed to the Company’s own equity. Based on meeting the above criteria, the conversion features are considered indexed to the Company’s common stock.

2. Classified in stockholders’ equity in its statement of financial position – ASC 815-40-25 states that to determine whether the embedded conversion feature would be classified in stockholders’ equity, the reporting entity needs to consider who controls the settlement and whether the settlement will be in shares or cash. ASC 815-40-25-2 states that if the contract provides the entity with the choice of net cash settlement or settlement in shares, the settlement in shares is assumed and contracts that require settlement in shares are equity instruments. The contract does not require a net cash settlement and the Company has the sole right to choose the settlement method. The Company also considered the additional conditions necessary for equity classification in ASC 815-40-25-10 and concluded that the conversion features met all the additional conditions necessary for equity classification. Therefore, the conversion features qualify to be classified in stockholders’ equity.

Based on our assessment and consistent with ASC 815-10-15-74(a), the conversion features were not required to be bifurcated and accounted for as a derivative under ASC 815.

In our future filings, beginning with our Form 10-Q for the quarter ending June 30, 2023, we will include the following accounting policy disclosure in the “Summary of Significant Accounting Policies” footnote:

Convertible Notes

The 2024, 2027 and 2028 Convertible Notes (“Convertible Notes”) are accounted for in accordance with ASC 470 and ASC 815. We evaluate all the embedded conversion options contained in the Convertible Notes to determine if there are embedded features that require bifurcation as a derivative as required by U.S. GAAP. Based on our analysis, we account for each of our Convertible Notes as single units of accounting, a liability, because we concluded that the conversion features do not require bifurcation as a derivative under ASC 815-15.

Read in the reply

Also in this review: closing letter, 2023-07-21

Form 10-K for the Fiscal Year Ended December 31, 2014

2015-10-26 to 2016-01-28 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2016-01-28
Form 10-Q for the Quarterly Period Ended June 30, 2015 · Notes to Condensed Consolidated Financial Statements
SEC asked
Collaborative Agreements Other Collaborations, page 19 1. Regarding the AbbVie, Janssen and Pfizer license and collaboration agreements, please tell us how, in determining units of accounting and allocation of arrangement consideration, you considered the right of these parties to elect additional targets in the future upon the payment of additional fees.
Rest of the question

Please provide us your analysis with reference to authoritative literature demonstrating why arrangement consideration was not allocated to this right.

HALO answered

No numbered answer found in the reply. Read the reply ↗

Form 10-Q for the Quarterly Period Ended June 30, 2015 · Notes to Condensed Consolidated Financial Statements
SEC asked
Collaborative Agreements Other Collaborations, page 19 1. Refer to your response to our prior comment one. Please provide us proposed disclosure to be included in future periodic filings addressing:  In your summary of significant accounting policies’ note the accounting policy you follow for the right of your collaborators to elect additional targets in the future; and  For each applicable agreement discussed in
Rest of the question

this note, the dollar amount to elect the additional target and your conclusion as to whether the right is substantive and not priced at a more than insignificant discount.

HALO answered

No numbered answer found in the reply. Read the reply ↗

Also in this review: request for more time, Oct 28, 2015, closing letter, 2016-01-28

Form 10-K

2013-12-20 to 2014-02-11 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2014-02-11
Results discussion (MD&A)Inventory
Note 2: Summary of Significant Accounting Policies · Research and Development Expenses, page F-13
SEC asked (1)
You disclose that you expense as incurred milestone payments made in connection with in-licensed technology or product candidates when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. Please tell us how this policy complies with the guidance in ASC 730-10-25-2c.
Rest of the question

In your response, please tell us whether you in-licensed any technology or product candidates that had alternative future uses in research and development projects or otherwise. Please provide us the proposed revised policy disclosure to be included in future periodic reports that evidences your compliance with the referenced guidance.

HALO answered
We respectfully submit that we have not in-licensed any technology or product candidates that had alternative future uses in research and development projects or otherwise. In response to the Staff’s comment, we propose to revise our disclosures in Note 2, Summary of Significant Accounting Policies, Research and Development Expenses as shown below (new text underlined and deleted text struck).
Rest of the answer

The proposed disclosures are prepared as of September 30, 2013, the end of our last fiscal quarter, but will be revised in the Form 10-K for the year ended December 31, 2013 to reflect financial information as of December 31, 2013.

“Notes to Condensed Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies

Research and Development Expenses

Research and development expenses include salaries and benefits, facilities and other overhead expenses, external clinical trial expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operations as incurred when these expenditures relate to our research and development efforts and have no alternative future uses. Costs related to purchases of API and the manufacturing of a collaboration product incurred after receiving approval from the FDA or comparable regulatory agencies in foreign countries for such product are capitalized as inventory. The manufacturing costs of API for Herceptin SC and HyQvia incurred after the receipt of the European marketing approvals are capitalized as inventory.

In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.

Milestone payments that we make in connection with in-licensed technology or product candidates for a particular research and development project that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic values are expensed as research and development costs at the time the costs are incurred.as incurred when there is uncertainty in receiving future economic benefits from the licensed technology or product candidates. We consider the future economic benefits from the licensed technology or product candidates to be uncertain until such licensed technology or product candidates are approved for marketing by the regulatory bodies such as the FDA or when other significant risk factors are abated. Management has viewed future economic benefits for all of our licensed technology to be uncertain and has expensed these amounts as incurred. We have no in-licensed technologies that have alternative future uses in research and development projects or otherwise.”

Form 10-Q for the quarterly period ended September 30, 2013

Management’s Discussion and Analysis of Financial Condition and Results of Operations Results of Operations, page 31

Read in the reply
In its next report

First report after the company's reply of Jan 17, 2014: 10-K filed Feb 28, 2014 ↗, against the 10-K filed Mar 1, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management’s Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 31
SEC asked (2)
You disclose in the last paragraph on page 32, related to the three-month period, and in the first paragraph on page 35, related to the nine-month period, that your cost of sales excludes the cost of inventory of Herceptin SC and HyQvia incurred prior to receipt of regulatory marketing approval.
Rest of the question

Please provide us proposed revised disclosure to be included in future periodic reports that includes:  the amount, by year, of manufacturing costs of API for Herceptin SC and HyQvia incurred prior to receiving the marketing approvals that was previously charged to research and development expense;  the estimated selling price or range of zero-cost/reduced-cost inventory you have at the latest balance sheet date presented and an indication as to the time period you expect to sell this inventory; and  the estimated cost of sales or a range, if determinable, as a percentage of selling price that you expect to incur after the zero-cost/reduced cost inventory has been consumed.

HALO answered
In our future filings, beginning with our Form 10-K for the year ended December 31, 2013, we will revise our disclosure in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, Results of Operations as shown below (new text underlined and deleted text struck). The proposed disclosures are prepared as of September 30, 2013, the end of our third fiscal quarter, but will be revised in the Form 10-K for the year ended December 31, 2013 to reflect financial information as of December 31, 2013.

“Management’s Discussion and Analysis of Financial Condition and
Rest of the answer

Results of Operations

Results of Operations

Three Months Ended September 30, 2013 Compared to Three Months Ended September 30, 2012

Cost of Product Sales – Cost of product sales were $0.7 million for the three months ended September 30, 2013 compared to $0.2 million for the three months ended September 30, 2012. The increase of $0.5 million in cost of product sales was mainly due to the increased product sales of Hylenex recombinant.

Cost of product sales of API for Herceptin SC excluded The the related manufacturing costs of API for Herceptin SC totaling $6.5 million that were incurred prior to receiving the marketing approval have been and thus were charged to research and development expenses in the periods such costs were incurred. Therefore, there was minimal cost of product sales of API for Herceptin SC recognized in the current period. Of the $6.5 million manufacturing costs, the amounts charged to research and development expenses were $1.0 million and $6.3 million for the three and nine months ended September 30, 2013, respectively, and zero and $0.2 million for the three months ended September 30, 2012 and twelve months ended December 31, 2012, respectively.

The estimated selling price of the zero-cost inventory of Herceptin SC API on hand as of September 30, 2013, was approximately $3.1 million. We expect to sell this inventory by the end of the first half of 2014. After this zero-cost inventory has been consumed, we expect the estimated cost of product sales to be approximately 83% of API product sales revenue. There was no HyQvia API inventory on hand as of September 30, 2013.

Based on the reintroduction of Hylenex recombinant in December 2011 and the European approvals of and Herceptin SC in August 2013 and HyQvia in May 2013, we expect cost of product sales to continue to increase through the end of 2013 as compared to 2012.

Nine Months Ended September 30, 2013 Compared to Nine Months Ended September 30, 2012

Cost of Product Sales – Cost of product sales were $2.7 million for the nine months ended September 30, 2013 compared to $0.4 million for the nine months ended September 30, 2012. The increase of $2.3 million in cost of product sales was mainly due to the $1.6 million increase in cost of product sales related to the increased Hylenex recombinant sales and a $0.6 million write-off of certain work-in-process and finished goods inventory.

Cost of product sales of API for Herceptin SC and HyQvia excluded The the related manufacturing costs of API for Herceptin SC and HyQvia totaling $7.4 million that were incurred prior to receiving the marketing approvals have been and thus were charged to research and development expenses in the periods such costs were incurred. Therefore, there was minimal cost of product sales of API for Herceptin SC and HyQvia recognized in the current period. Of the $7.4 million manufacturing costs, the amounts charged to research and development expenses were $6.4 million for the nine months ended September 30, 2013 and $0.6 million and $1.0 million for the nine months ended September 30, 2012 and twelve months ended December 31, 2012, respectively.

The estimated selling price of the zero-cost inventory of Herceptin SC API on hand as of September 30, 2013, was approximately $3.1 million. We expect to sell this inventory by the end of the first half of 2014. After this zero-cost inventory has been consumed, we expect the estimated cost of product sales to be approximately 83% of API product sales revenue. There was no HyQvia API inventory on hand as of September 30, 2013.

Based on the reintroduction of Hylenex recombinant in December 2011 and the European approvals of Herceptin SC in August 2013 and HyQvia in May 2013, we expect cost of product sales to continue to increase through the end of 2013 as compared to 2012.”

***

The Company acknowledges that:

The Company is responsible for the adequacy and accuracy of the disclosure in the Company’s SEC filings;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and

The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Jan 17, 2014: 10-K filed Feb 28, 2014 ↗, against the 10-K filed Mar 1, 2013 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Dec 26, 2013, closing letter, 2014-02-11

Form 10-K for the Fiscal Year Ended December 31, 2011

2012-08-06 to 2012-10-16 · 5 questions · 2 letters from the SEC, 2 from the company
Review closed 2012-10-16
RevenueResults discussion (MD&A)
Operations · Overview, page 30
SEC asked (1)
Please provide us proposed disclosure to be included in future periodic reports regarding your collaboration agreements with Roche, Baxter, ViroPharma, and Intrexon to provide the range of potential royalty payments to be made under the agreements within ten percentage points (e.g., “high single-digits,” “teens”) and the duration of each agreement.
Rest of the question

To the extent the duration of your agreements is based on the duration of the underlying royalty obligation, please provide a full description of the term of the royalty obligation.

HALO answered
In response to the Staff’s comment, we propose to revise our disclosures in the Management’s Discussion and Analysis of Financial Conditions and Results of Operations to provide the range of potential royalty payments and the term of the royalty obligation under our collaborative agreements in our future filings, beginning with our Form 10-Q for the quarter ending September 30, 2012, as shown below (new text underlined and deleted text struck). We will make the same proposed revisions in the corresponding notes to our consolidated financial statements.
Rest of the answer

The proposed disclosures are prepared as of March 31, 2012, the end of our first fiscal quarter, but will be revised in the Form 10-Q for the quarter ending September 30, 2012 to reflect financial information as of September 30, 2012.

“Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Critical Accounting Policies and Estimates

Revenue Recognition

Revenues under Collaborative Agreements

Roche Partnership

In December 2006, we and Roche entered into the Roche Partnership under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and up to thirteen Roche target compounds. As of March 31, 2012, we have received $57 million from Roche, including the $20 million upfront license fee payment for the application of rHuPH20 to the initial three Roche exclusive targets, $20 million in connection with Roche’s election of two additional exclusive targets and annual license maintenance fees for the right to designate the remaining targets as exclusive targets, $13 million in clinical development milestone payments and a $4 million regulatory milestone payment. If Roche successfully develops all five exclusive targets and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $178 million, including up to $17 million for the achievement of clinical development milestones, up to $16 million for the achievement of regulatory milestones and up to $145 million for the achievement of sales-based milestones. Under the terms of the Roche Partnership, Roche will also pay us royalties on product sales for each exclusive target. a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the Roche Partnership continues in effect until the expiration of Roche’s obligation to pay royalties. Roche has the obligation to pay royalties with respect to each product in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country.

Roche currently retains the option to develop and commercialize rHuPH20 with three additional targets under the Roche Partnership, provided that it continues to pay annual maintenance fees to us. For products developed for each of the additional targets, Roche may pay us upfront and milestone payments of up to $47 million per target, as well as royalties on product sales, for each of the additional targets consisting of a mid-single digit percent of the net sales of such products.

Due to our continuing involvement obligations (for example, support activities associated with rHuPH20), revenues from the upfront payment, exclusive designation fees and annual license maintenance fees were deferred and are being recognized over the term of the Roche Partnership. We have determined that the clinical and regulatory milestones are substantive; therefore, we expect to recognize such clinical and regulatory milestone payments as revenue upon achievement. In addition, we have determined that the sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, we will recognize such sales-based milestone payments as revenue upon achievement of the milestone. In March 2012, Roche submitted a Line Extension

Application to the European Medicines Agency for Herceptin SC. Upon achievement of this milestone, we recognized a regulatory milestone payment of $4 million as revenue under collaborative agreements in accordance with the Milestone Method in the three months ended March 31, 2012. For the three months ended March 31, 2011, we recognized $5 million as revenue under collaborative agreements in accordance with the Milestone Method related to the achievement of certain clinical milestone pursuant to the terms of the Roche Partnership.

Gammagard Partnership

In September 2007, we and Baxter entered into the Gammagard Partnership under which Baxter obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with HyQ. As of March 31, 2012, we have received $13 million under the Gammagard Partnership, including the $10 million upfront license fee payment and a $3 million regulatory milestone payment. If Baxter successfully receives marketing approval for the licensed product candidate and achieves pre-agreed sales targets, we could receive additional milestone payments of up to $34 million for the achievement of sales-based milestones. In addition, Baxter will pay royalties on the sales, if any, of the products that result from the collaborationus a royalty on each product commercialized under the agreement consisting of a mid-single digit percent of the net sales of such product. The Gammagard Partnership is applicable to both kit and formulation combinations. Baxter assumes all development, manufacturing, clinical, regulatory, sales and marketing costs under the

Gammagard Partnership, while we are responsible for the supply of rHuPH20 enzyme. We perform research and development activities at the request of Baxter, which are reimbursed by Baxter under the terms of the Gammagard Partnership. In addition,

Baxter has certain product development and commercialization obligations in major markets identified in the Gammagard Partnership. Unless terminated earlier in accordance with its terms, the Gammagard Partnership continues in effect until the expiration of Baxter’s obligation to pay royalties. Baxter has the obligation to pay royalties, with respect to each product in each country, during the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country.

revenues from the upfront payment were deferred and are being recognized over the term of the Gammagard Partnership. We have determined that sales-based milestone payments are similar to royalty payments and are not considered milestone payments under the Milestone Method of revenue recognition; therefore, such payments will be recognized as revenue upon achievement of the milestone. There were no milestone payments recognized as revenue under the terms of the Gammagard Partnership for the three months March 31, 2012 and 2011.

ViroPharma and Intrexon Partnerships

Effective May 2011, we and ViroPharma entered into the ViroPharma Partnership. As of March 31, 2012, we have received $12 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment and a $3 million clinical development milestone payment. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive an annual exclusivity fee of $1 million commencing May 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive royalties on product sales by ViroPharmaa royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such product.

Unless terminated earlier in accordance with its terms, the ViroPharma Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the

ViroPharma Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country.

Effective June 2011, we and Intrexon entered into the

Intrexon Partnership. As of March 31, 2012, we have received a nonrefundable upfront license fee payment of $9 million from Intrexon. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive an annual exclusivity fee of $1 million commencing June 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the

Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive royaltiesa royalty on each product sales at a royalty rate which increases with net sales of productcommercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. Unless terminated earlier in accordance with its terms, the Intrexon

Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country.

We identified the deliverables at the inception of the ViroPharma and Intrexon Partnerships which are the license, research and development services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these units of accounting were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the partners. The arrangement consideration was allocated to the deliverables based on the relative selling price method.

The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable other than for the potential effects of refund rights, concessions or performance bonuses. As such, we excluded from such allocable consideration the milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt because such payments are not considered fixed or determinable. Such payments will be evaluated separately as the related contingencies are resolved. Based on the results of our analysis, we allocated the $9 million upfront license fee to the license deliverable under the ViroPharma arrangement and the $9 million upfront license fee to the license deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in both the ViroPharma Partnership and Intrexon Partnership. However, the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received. As a result, we recognized the $9 million upfront license fee received under the

ViroPharma Partnership and the $9 million upfront license fee received under the Intrexon Partnership as revenues under collaborative agreements upon receipt of the upfront license fees.

We will recognize the annual exclusivity fees as revenues under collaborative agreements when they are earneddue and payable on each anniversary of the effective date and such amounts will be included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We will recognize reimbursements for amounts allocated to research and development services as revenues under collaborative agreements as the related services are deliveredperformed. We will recognize payments fromamounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the partners and the related title and risk of loss and damages have passed to the partners. We cannot predict the timing of delivery of research and development services and API as they are at the partners’ requests.

We are eligible to receive additional cash payments upon the achievement by the partners of specified development, regulatory and sales-based milestones. We have determined that each of the development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone Method of revenue recognition; therefore, we will recognize the sales-based milestone payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. There were no milestone payments recognized as revenue under the collaborative agreements under these partnerships for the three months ended March 31, 2012 and 2011.”

Read in the reply
Item 15. Exhibits and Financial Statement Schedules, page 55
SEC asked (2)
We note that you derived 22% and 16% of your revenues in 2011 from your agreements with ViroPharma and Intrexon and that each agreement includes substantial potential royalty and milestone payments. In addition, we note that your agreement with Intrexon represents a related party transaction involving your director, Randall J.
Rest of the question

Kirk., who also serves as chief executive officer, chairman of the board of directors and major shareholder of Intrexon. In light of these factors, your agreements with Intrexon and ViroPharma appear to represent material contracts that should be filed as exhibits. Please file your agreements with ViroPharma and Intrexon as promptly as possible pursuant to Item 601(b)(10) of Regulation S-K. In the alternative, if you do not believe that these agreements are required to be filed as exhibits, please provide a legal analysis in support of your position.

HALO answered
We respectfully submit that we have determined that our collaboration and license agreements with ViroPharma and Intrexon are not material contracts required to be filed pursuant to Item 601(b)(10) of Regulation S-K, as each agreement was entered into in the ordinary course of business, our business is not substantially dependent on either of the agreements and the agreements are not otherwise material to us.

As described in our Annual Report on Form 10-K for the year ended December 31, 2011, we have collaborative partnerships with several companies, including ViroPharma and Intrexon, under
Rest of the answer

which we receive (or may receive) payments for license fees, milestone payments for specific achievements, royalties and reimbursements of research and development services pursuant to collaboration and license agreements. We enter into these collaboration and license agreements in the ordinary course of our business. We also note that these agreements are of a type that ordinarily accompanies the type of business that we conduct.

These collaboration and license agreements generally require the licensee to pay to us a one-time, nonrefundable, upfront license fee at the time the agreement is executed. We therefore may derive a substantial portion of our revenues from one company in the year in which the parties enter into a collaboration and license agreement, but because this license fee is a one-time payment, we may derive little or no revenue from the licensee in the subsequent years, as other payments due to us under these agreements are contingent upon the occurrence of specific achievements.

While 22% and 16% of our total revenues for the year ended December 31, 2011 were derived from ViroPharma and Intrexon, respectively, these percentages reflect the $9 million one-time license fee we received from ViroPharma and $9 million one-time license fee we received from Intrexon in 2011 upon entry into the respective collaboration and license agreements. While these agreements accounted for a substantial portion of our revenue for a specific fiscal year, our business as a whole is not substantially dependent upon either agreement (as required for filing by Item 601(b)(10)(ii)(B) of Regulation S-K), as we may not generate any material revenues under either of the agreements beyond the one-time, nonrefundable, upfront license fee. We do not anticipate deriving a substantial portion of our revenue for 2012 from either ViroPharma or

Intrexon at this time. We recognize that, over time, one or more of these agreements may need to be filed if our business becomes substantially dependent on that relationship.

In addition, with respect to the agreement with Intrexon, we acknowledge that the agreement with Intrexon represents a related party transaction involving our director, Randall J. Kirk, who also serves as chief executive officer, chairman of the board of directors and major shareholder of Intrexon. However, we respectfully submit that, notwithstanding the related party transaction, the agreement with Intrexon does not constitute a material contract required to be filed under Item 601(b)(10)(ii)(A) of Regulation S-K. We respectfully note that, unlike Item 404 (which looks to the presence of a direct or indirect material interest) Item 601(b)(10)(ii)(A) provides in relevant part that any contract to which directors, officers, promoters, voting trustees, security holders named in the registration statement or report, or underwriters are parties shall be filed except where immaterial in amount or significance. While Randal J.

Kirk serves as chief executive officer, chairman of the board of directors and major shareholder of Intrexon, Mr. Kirk is not a party to the agreement. Further, the collaboration and license agreement with Intrexon was negotiated at arms-length, was reviewed and approved by our Board of Directors in accordance with our related party transaction policy and contains substantially similar terms to our other collaboration and license agreements entered into in the ordinary course of business.

In light of the foregoing, we do not believe that our agreements with ViroPharma and Intrexon are required to be filed as exhibits. We will review the significance of these agreements on an ongoing basis and represent to the Staff that we will continue to assess our dependence upon such agreements and file such agreements if and when we determine that our business is then substantially dependent upon such agreements.

Read in the reply
In its next report

First report after the company's reply of Aug 31, 2012: 10-Q filed Nov 8, 2012 ↗, against the 10-Q filed May 7, 2012 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Notes to Consolidated Financial Statements
SEC asked (3)
Collaborative Agreements ViroPharma and Intrexon Partnerships, page F-18 3. With respect to the agreements executed in 2011 with ViroPharma and Intrexon, you recognized a total of $18 million in revenue attributable to upfront license fee payments based on your determination that the licenses have stand-alone value.
Rest of the question

You also determined that the research and development services and API supply are deliverables that have standalone value. Please provide us your analysis of the accounting for each arrangement by addressing the following:  Please provide us your analysis demonstrating that neither the research and development nor the supply agreements is necessary in order to obtain value from the license;  You state “the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received.” Please tell us how your policy complies with ASC 605-25-30-5 which states that the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-2530-2 and 30-4, or the noncontingent amount.  Please provide us proposed disclosures to be included in future periodic reports of the total arrangement consideration and indicate the amount allocated to each deliverable, and;  Provide us an analysis of how you determined the total arrangement consideration and the amount allocated to each deliverable.

HALO answered
To account for the ViroPharma and Intrexon arrangements, we identified the deliverables included within each arrangement and determined if there were separate units of accounting as defined in ASC 605-25.

ASC 605-25-25-4 states a vendor should evaluate all the deliverables in an arrangement to determine whether they can be separated into multiple units of accounting. That evaluation should be performed at the inception of the arrangement and as each item in the arrangement is delivered.
Rest of the answer

ASC 605-25-25-5 states in an arrangement with multiple deliverables, the delivered item or items shall be considered a separate unit of accounting if both of the following criteria are met:

1)

The delivered item or items have value to the customer on a standalone basis,

2)

If the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items is considered probable and substantially in the control of the vendor.

If both of the separation criteria are met, separation of the deliverables is not optional. The deliverables in an arrangement that meet the separation criteria above must be accounted for as separate units of accounting for revenue recognition purposes. If either of the separation criteria is not met for a delivered item in a multiple-element arrangement, the delivered item is accounted for as a combined unit of accounting with the undelivered item(s).

The

ViroPharma and Intrexon arrangements have identical deliverables; therefore, we will address them together. At the inception of the ViroPharma and Intrexon arrangements, we identified three deliverables which are (1) the license to our proprietary enzyme, the recombinant human hyalurondiase (rHuPH20), (2) research and development (R&D) services and (3) supply of rHuPH20 active pharmaceutical ingredient (API). We determined that the license, R&D services and rHuPH20 API supply individually represent separate units of accounting, because each deliverable has standalone value.

The first criterion that must be met to separately account for deliverables in a multiple-element arrangement is that the delivered item or items have value to the customer on a standalone basis. ASC 605-25-25-5(a) states that a delivered item has standalone value to the customer when either:

Any vendor can sell that item separately, or

The customer could resell that item on a standalone basis. In the context of a customer’s ability to resell the delivered item(s), this criterion does not require the existence of an observable market for the deliverable(s).

The second criteria that must be met to separately account for deliverables in a multiple-element arrangement is that in situations in which a general right of return exists for the delivered item, delivery or performance of the undelivered items(s) is considered probable and is substantially within the control of the company. There is no general right of return within the ViroPharma and Intrexon collaboration agreements and therefore this criterion was not considered further.

License Standalone Value determined that the delivered license has standalone value because upon the receipt of the license, ViroPharma and Intrexon are able to use the license for its intended purpose without the receipt of the remaining deliverables. We believe that

ViroPharma and Intrexon each has internal product development capabilities and/or can utilize expertise and resources from other vendors to develop and move their respective programs forward without our R&D services. We also believe that

ViroPharma and Intrexon can acquire rHuPH20 API supply from other vendors to further develop and move their respective programs forward without the supply of rHuPH20 API from us.

In a December 7, 2009 SEC Staff speech by Arie Wildenburg, the Staff illustrated in an example that it would be possible to demonstrate standalone value, despite not selling the item separately or the customer not having the ability to resell the item on a standalone basis. The Staff also concluded that the analysis of standalone value should be based on the individual facts and circumstances of each arrangement. Below is an excerpt from that speech (emphasis added).

“Consider an arrangement that contains the following two deliverables:

1. Delivered Item: Biotech License of Technology

2. Undelivered Item: Proprietary Research and Development Services

In this example, assume the Biotech owns certain technology that will be used in the development of a new drug, and since we’re being creative; let’s imagine it’s a drug that can cure hair loss without any side effects. This technology is unique, such that no other vendor sells a similar item. Also, assume the Biotech will never sell this technology on its own;

rather it will always be sold with the R&D services, which are essential in order to derive value from the technology. Finally, as a protective measure, the Biotech has included a contractual restriction that prevents the customer from sub-licensing or reselling the technology.

Given this set of facts, the license does not have stand-alone value. First, the technology is not sold separately by anyone. Second, the customer cannot resell the technology. Therefore, the license should be combined with the R&D services as a single unit of accounting.

However, there may be a number of ways in which this fact pattern could be modified such that the license would have stand-alone value.

For example, what if the R&D services are not proprietary; rather such services can be, and in some circumstances are, provided by other vendors. Even though the license is useless without the R&D services and the customer is contractually restricted from reselling the technology, the fact that other vendors provide such R&D services is an indication that the license might have stand-alone value. This is because the vendor can license the technology separately while another vendor provides the on-going R&D services.

In summary, the analysis of stand-alone value must be based on the individual facts and circumstances for each arrangement.”

We also considered position papers by Ernst & Young, KPMG and PwC that support the determination of standalone value in the absence of the item being sold separately or the customer not having the ability to sell the item on a standalone basis. For the Staff’s convenience, we have attached the relevant extracts as Attachment

A to this response letter: Ernst & Young’s Technical Line of April 2, 2010 – Effects of New Multiple Element Revenue Guidance on Life Sciences R&D Collaborations; KPMG’s Accounting for Revenue Arrangements with

Multiple Deliverable of November 2010; and PWC’s Dataline whitepaper of January 2011.

Based on our interpretation of the aforementioned

SEC Staff speech and the accounting firms’ publication, we determined that, even though a customer may be precluded from reselling the license, a customer’s ability to use the delivered item for its intended purpose without the receipt of the remaining deliverables may indicate that the item has standalone value. The SEC Staff speech indicates that the customer is able to obtain the value intended from the delivered item and the customer could have purchased the delivered item on a standalone basis. We also considered that the absence of a secondary market does not preclude this license from having standalone value. We believe that upon delivery of the license to the collaborators, ViroPharma and Intrexon were each in a position to be able to use the delivered license for its intended purpose and could move their respective programs forward utilizing expertise and resources from either other vendors or their own internal capabilities, without us delivering the remaining deliverables included in the agreements.

R&D Services Standalone Value

ViroPharma is an international, publicly-traded biopharmaceutical company with 247 employees. ViroPharma has two marketed products, Cinryze® (C1 esterase inhibitor [human]) and Vancocin® and a robust pipeline with one product candidate under approval review, three product candidates in phase 2 clinical trials and one product candidate in preclinical stage of development.

Intrexon, founded in 1998, is a privately held synthetic biology company with over 400 patents and patent applications.

Intrexon employs over 200 employees with facilities in Maryland, Virginia, North Carolina and California.

The proprietary technology licensed by us to ViroPharma and Intrexon included in the license agreements relates primarily to our proprietary rHuPH20 enzyme. rHuPH20 enzyme can be applied to existing and developmental products of biopharmaceutical companies that market drugs requiring or benefiting from injection via subcutaneous route of administration. rHuPH20 is used as an active ingredient/excipient for enhancing the dispersion and/or absorption of the collaborators’ product or product candidate. The ViroPharma license agreement provides

ViroPharma the right to use our rHuPH20 technology in the development of a subcutaneous injectable formulation of ViroPharma’s existing product, Cinryze. The Intrexon license agreement provides Intrexon the right to use our rHuPH20 technology in the development of a subcutaneous injectable formulation of Intrexon’s licensed product candidates.

Pursuant to the terms of the ViroPharma and Intrexon agreements, ViroPharma and Intrexon are solely responsible for conducting development, manufacture, regulatory approval and commercialization of their respective licensed product candidates on their own. At the collaborators’ request, we will provide R&D services to the collaborators and are reimbursed at contractually determined rates. Although ViroPharma and Intrexon are solely responsible for conducting the development of their respective licensed product candidates, we believe they will use Halozyme to a certain extent for some of the R&D services. Accordingly, we have considered the delivery of the R&D services as a deliverable within the arrangement. As rHuPH20 is used as an active ingredient with the collaborators’ products and/or product candidates, the R&D services to be delivered by us mainly consist of development and regulatory services with respect to the rHuPH20 component of the product candidates. We determined that R&D services are not proprietary to us based on the facts that:

As rHuPH20 enzyme and hyaluron protein have been well characterized in life sciences, other vendors can provide similar R&D services as we have contracted with third parties to perform similar types of services in the past, and

Based on our observations during due diligence, we believe that ViroPharma and Intrexon each has the expertise and internal capabilities to perform such R&D services.

Once these entities have the rights to use the rHuPH20 technology, we believe ViroPharma and

Intrexon each can utilize resources from either other vendors or their own internal capabilities to move their respective programs forward without us providing R&D services. In addition, both ViroPharma and Intrexon have the right under the terms of the license agreements to transfer know-how to a third party solely for the purpose of developing, manufacturing or commercializing the licensed product candidates. As such, utilizing Halozyme’s R&D services is not necessary in order for ViroPharma and Intrexon to be able to obtain the value intended from the licenses.

rHuPH20 API Supply Standalone Value

Pursuant to the terms of the ViroPharma and Intrexon agreements, we will provide rHuPH20 API to the collaborators at their request and are reimbursed at our cost plus a margin. Although Viropharma and Intrexon are solely responsible for the manufacture of their respective licensed product candidates, as rHuPH20 is used as an active ingredient with their respective licensed products and/or product candidates, we believe they will purchase rHuPH20 API from us. As such, we consider the delivery of rHuPH20 API as a deliverable within the ViroPharma and Intrexon arrangements.

Management believes the rHuPH20 API supply has standalone value because the manufacturing process can be provided by other vendors. In fact, we have outsourced all of our manufacturing activities to third-party contract manufacturing organizations and plan to continue to do so. In addition, the agreements with ViroPharma and Intrexon include provisions that, in the event that we fail to deliver certain amount of rHuPH20 API as required by ViroPharma and Intrexon, allow

ViroPharma and Intrexon to contract directly with the contract manufacturing organizations for their rHuPH20 API supplies. As such, we determined that rHuPH20 API supply from Halozyme is not necessary in order for ViroPharma and Intrexon to be able to obtain the value intended from the license.

You state “the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received.” Please tell us how your policy complies with ASC 605-25-30-5 which states that the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount.

Response:

Pursuant to the terms of the ViroPharma license agreement, at the inception of the arrangement we received a nonrefundable upfront license fee payment of

$9 million and are entitled to receive payments upon achievement of certain development and regulatory milestones; annual exclusivity fees as long as the agreement is in effect; royalties on product sales and payments for R&D services and supply of rHuPH20 API if requested by ViroPharma.

Pursuant to the terms of the Intrexon license agreement, at the inception of the arrangement we received a nonrefundable upfront license fee payment of $9 million and are entitled to receive payments upon achievement of certain development and regulatory milestones and a sales-based milestone; annual exclusivity fees as long as the agreement is in effect; royalties on product sales and payments for R&D services and supply of rHuPH20 API if requested by Intrexon.

We determined that, in accordance with ASC 605-25, the license, R&D services and rHuPH20 API supply individually represent separate units of accounting. The guidance in ASC 605-25-30 requires that the arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. ASC 605-25-30-5 states that the amount allocable to the delivered item or items is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions. That is, the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount. As such, we excluded from the allocable arrangement consideration contingent payments regardless of the probability of receipt. We determined that the milestone, annual exclusivity fees and royalty payments are contingent and thus not considered fixed or determinable at the inception of the arrangements; therefore, such payments are excluded from the allocable arrangement consideration. Such payments will be evaluated separately as the related contingencies are resolved.

The license and all related know-how were delivered to ViroPharma and Intrexon following the execution of each agreement. We determined that the relative selling price of the license under the ViroPharma and Intrexon arrangements were far in excess of the upfront license fee of $9 million; however, we had received only the nonrefundable and noncontingent upfront license fee of $9 million each under the ViroPharma and Intrexon agreements at the inception of the arrangements. Therefore, we concluded that at the inception of the arrangements, the amount of arrangement consideration allocable to the delivered item, the license, is limited to the $9 million in nonrefundable upfront license fee payment we received each under the ViroPharma and Intrexon arrangements for the quarter ended June 30, 2011. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services and API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license in the ViroPharma and Intrexon arrangements. As future payments become fixed or determinable, we will reassess the total arrangement consideration and the amount allocable to each deliverable accordingly.

Please provide us proposed disclosures to be included in future periodic reports of the total arrangement consideration and indicate the amount allocated to each deliverable, and;

Response:

In our future filings, beginning with our Form 10-Q for the quarter ending September 30, 2012, we will revise our disclosure in Note 3, Collaborative Agreements – ViroPharma and Intrexon

Partnerships as shown below (new text underlined and deleted text struck). The proposed disclosures are prepared as of March 31, 2012, the end of our first fiscal quarter, but will be revised in the Form 10-Q for the quarter ending

September 30, 2012 to reflect financial information as of September 30, 2012.

“Notes to Condensed

Consolidated Financial Statements

3. Collaborative Agreements

Effective May 10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma’s commercialized product, Cinryze® (C1 esterase inhibitor [human]) (the “ViroPharma Partnership”). In addition, the license provides ViroPharma with exclusivity to C1 esterase inhibitor and to the hereditary angioedema indication, along with three additional orphan indications. As of March 31, 2012, we have received $12 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment and a $3 million clinical development milestone payment. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on May 10, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive royalties on future product sales by ViroPharmaa royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the

ViroPharma Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate.

Effective June 6, 2011, we and Intrexon entered into a collaboration and license agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon’s recombinant human alpha 1-antitrypsin (rHuA1AT) (the “Intrexon Partnership”). In addition, the license provides Intrexon with exclusivity for a defined indication (“Exclusive

Field”). As of March 31, 2012, we have received a nonrefundable upfront license fee payment of $9 million from Intrexon. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on June 6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. Intrexon is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive royaltiesa royalty on each product sales at a royalty rate which increases with net sales of productcommercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. Unless terminated earlier in accordance with its terms, the Intrexon Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. Intrexon may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with respect to the terminated product, as applicable) will terminate. Intrexon’s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors.

We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these units of accounting was determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the partners. The arrangement consideration was allocated to the deliverables based on the relative selling price method.

other than for the potential effects of refund rights, concessions or performance bonuses. As such, we excluded from such allocable consideration the milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt because such payments are not considered fixed or determinable. Such payments will be evaluated separately as the related contingencies are resolved. Based on the results of our analysis, we allocated the $9 million upfront license fee to the license deliverable under the ViroPharma arrangement and the $9 million upfront license fee to the license deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in both the ViroPharma Partnership and Intrexon Partnership. However, the amount of allocable arrangement consideration is limited to amounts that are fixed or determinable; therefore, the amount allocated to the license was only to the extent of cash received. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Partnership and the $9 million upfront license fee received under the

Intrexon Partnership as revenues under collaborative agreements upon receipt of the upfront license fees.

We will recognize the annual exclusivity fees as revenues under collaborative agreements when they are earneddue and payable on each anniversary of the effective date and such amounts will be included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We will recognize reimbursements foramounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We will recognize revenue fromamounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the partners and the related title and risk of loss and damages have passed to the partners. We cannot predict the timing of delivery of research and development services and API as they are at the partners’ requests.

We are eligible to receive additional cash payments upon the achievement by the partners of specified development, regulatory and sales-based milestones. We have determined that each of the development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone

Method of revenue recognition; therefore, we will recognize the sales-based milestone payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. There were no milestone payments recognized as revenue under the collaborative agreements under these partnerships for the three months ended March 31, 2012 and 2011.”

Provide us an analysis of how you determined the total arrangement consideration and the amount allocated to each deliverable.

Response:

Pursuant to the guidance in ASC 605-25-30, we allocated the arrangement consideration at the inception of the arrangement to all deliverables on the basis of their relative selling price. ASU 2009-13 provides the hierarchy for estimating selling price as follows:

Vendor-specific objective evidence (“VSOE”) or the price at which the vendor regularly sells the item on a standalone basis,

If VSOE does not exist, the third-party evidence (“TPE”) of selling price must be used, or

If neither VSOE nor TPE exist, the vendor uses its best estimate of the selling price, which is the price at which the vendor would transact if the deliverable were sold regularly on a standalone basis.

The VSOE and TPE do not exist due to the uniqueness of our license. Nor are there other vendors that sell similar technology. Therefore, we used our best estimate of the selling price in the allocation of the ViroPharma and Intrexon arrangement consideration. The best estimated selling price for the units of accounting within the ViroPharma and Intrexon arrangements were determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of R&D services to be performed by the collaborators. We estimated the selling price of the license under the ViroPharma and Intrexon agreements utilizing a discounted net present value model. The model was developed as part of our due diligence to help determine the estimated value of the arrangement. We determined that the estimated selling prices of the respective licenses in the ViroPharma and Intrexon arrangements were individually far in excess of the upfront license fees that we received under each arrangement.

R&D services to be provided by us to the collaborators will be reimbursed by ViroPharma and Intrexon based on the labor rate that was agreed upon which was based on typical rates charged for similar services in the biotech industry. We used our best estimate of selling price after considering TPE of selling price, and concluded that the agreed-upon labor rate represents the best estimated selling price of R&D services. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license.

Supply of rHuPH20 API to be provided by us to the collaborators are at the request of the collaborators and are being paid by ViroPharma and Intrexon at our cost plus a certain margin that was agreed upon which was not inconsistent with biotech contract manufacturing arrangements. We also took into consideration what we had charged other collaborators in the past for similar supply services to further support the estimated selling price. We concluded that the rate of our cost plus the agreed-upon margin represents the best estimated selling price of the API supply. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the $9 million upfront license fee being allocated to the license.

ASC 605-25-30-5 states that the amount allocable to the delivered item or items is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions. That is, the amount allocable to the delivered item or items is the lesser of the amount otherwise allocable in accordance with paragraphs 605-25-30-2 and 30-4, or the noncontingent amount. At the inception of the arrangements, we have received only the nonrefundable, noncontingent upfront license fees; therefore, we concluded that at the inception of the arrangements, the amount of arrangement consideration allocable to the delivered item, the license, is limited to the $9 million upfront license fee payment we received each under the ViroPharma and Intrexon arrangements for the quarter ended June 30, 2011. Because the best estimated selling price of the license was significantly higher than the $9 million upfront license fee and the R&D services and API supply will be paid at amounts which approximate our best estimate of their selling prices, any relative selling price allocation would result in the

$9 million upfront license fee being allocated to the license in the ViroPharma and Intrexon arrangements.

The milestone, annual exclusivity fee and royalty payments are contingent payments and not considered fixed or determinable at the inception of the arrangements; therefore, such payments are excluded from the allocable arrangement consideration. Contingent amounts will be evaluated separately as the related contingencies are resolved. We will also continue to evaluate the consideration for R&D services and supply of rHuPH20 API as these services are requested to be provided by us to ViroPharma and Intrexon. To the extent of materiality, we will reassess the allocable arrangement consideration and reallocate to the units of accounting in the arrangements accordingly.

Item 2.

Read in the reply
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of · Operations, page 18
SEC asked (4)
We note your disclosure on page 23 that the U.S. Food and Drug Administration has requested additional data to complete its review of Baxter’s HyQ BLA. Please advise us, with a view towards disclosure in your filings, as to the specific additional data requested by the FDA.
HALO answered
We have already provided additional disclosure regarding the specific additional data requested by FDA in our Form 10-Q for the Quarterly Period Ended June 30, 2012, filed on August 9, 2012, under Item 2, Management’s Discussion and Analysis of Financial

Condition and Results of Operations – Product and Product Candidates, Baxter Gammagard Partnership, as follows:

“On

August 1, 2012, we announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter’s HyQ BLA.
Rest of the answer

The CRL requested additional preclinical data to support the BLA. The primary issues raised in the CRL focused on non-neutralizing antibodies generated against rHuPh20 and the possible effects of these antibodies on reproduction, development and fertility. Elevated anti-rHuPH20 antibody titers were detected in the registration trial, but have not been associated with any adverse events. Pending Baxter and us providing additional preclinical data sufficient to address the regulatory questions, CBER has requested that patients should no longer be dosed with rHuPH20 in the Baxter HyQ program. Baxter has announced that individuals enrolling in ongoing HyQ clinical studies in the U.S. will now be treated with Baxter’s immune globulin therapy without rHuPH20. We and Baxter expect these requests will require additional time to complete and will delay the companies’ anticipated regulatory review and approval timelines.”

***

In connection with the Company’s response to the Staff’s comments, the Company acknowledges that:

The Company is responsible for the adequacy and accuracy of the disclosure in the Company’s SEC filings;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Aug 31, 2012: 10-Q filed Nov 8, 2012 ↗, against the 10-Q filed May 7, 2012 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Notes to Consolidated Financial Statements
SEC asked
Collaborative Agreements ViroPharma and Intrexon Partnerships, page F-18 1. With respect to the second and third bullet of comment three, your reference to fixed and determinable is not appropriate. Please revise your proposed disclosure to comply with ASC 605-25-30-5.
HALO answered
In response to the Staff’s comment above, we will revise our disclosure in Note 3, Collaborative Agreements – ViroPharma and Intrexon Partnerships. The proposed disclosure as shown below is presented with changes marked against the previous proposed disclosure in our response to the third bullet of comment three, in our response letter dated August 31, 2013.
Rest of the answer

The proposed disclosure is prepared as of March 31, 2012, the end of our first fiscal quarter, but will be revised in the Form 10-Q for the quarter ended September 30, 2012 to reflect financial information as of September 30, 2012.

“Notes to Condensed Consolidated Financial Statements”

3. Collaborative Agreements

ViroPharma and Intrexon Partnerships

Effective May 10, 2011, we and ViroPharma entered into a collaboration and license agreement, under which ViroPharma obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of ViroPharma’s commercialized product, Cinryze® (C1 esterase inhibitor [human]) (the “ViroPharma Partnership”). In addition, the license provides

ViroPharma with exclusivity to C1 esterase inhibitor and to the hereditary angioedema indication, along with three additional orphan indications. As of March 31, 2012, we have received $12 million from ViroPharma, including the $9 million nonrefundable upfront license fee payment and a $3 million clinical development milestone payment. If ViroPharma successfully develops the licensed product candidate, we could receive additional milestone payments of up to $41 million for the achievement of development and regulatory milestones. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on May 10, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. ViroPharma is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by ViroPharma. In addition, we are entitled to receive additional cash payments potentially totaling $10 million upon achievement of certain development and regulatory milestones for each product targeting the treatment of any of the three additional orphan indications. We are also entitled to receive a royalty on each product commercialized under the agreement consisting of ten percent of the net sales of such product. Unless terminated earlier in accordance with its terms, the ViroPharma Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the ViroPharma Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. ViroPharma may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to ViroPharma (in total or with respect to the terminated product, as applicable) will terminate.

Effective June 6, 2011, we and Intrexon entered into a collaboration and license agreement, under which Intrexon obtained a worldwide exclusive license for the use of rHuPH20 enzyme in the development of a subcutaneous injectable formulation of Intrexon’s recombinant human alpha 1-antitrypsin (rHuA1AT) (the

“Intrexon Partnership”). In addition, the license provides Intrexon with exclusivity for a defined indication (“Exclusive Field”). As of March 31, 2012, we have received a nonrefundable upfront license fee payment of $9 million from Intrexon. If Intrexon successfully develops the licensed product candidate and achieves the pre-agreed sales target, we could receive additional milestone payments of up to $54 million, including $44 million for the achievement of development and regulatory milestones and $10 million for the achievement of a sales-based milestone. In addition, so long as the agreement is in effect, we are entitled to receive a nonrefundable annual exclusivity fee of $1 million commencing on

June 6, 2012 and on each anniversary of the effective date of the agreement thereafter until a certain development event occurs. Intrexon is solely responsible for the development, manufacturing and marketing of any products resulting from this partnership. We are entitled to receive payments for research and development services and supply of rHuPH20 API if requested by Intrexon. In addition, we are entitled to receive additional cash payments potentially totaling $10 million for each product for use outside the Exclusive Field upon achievement of development and regulatory milestones. We are also entitled to receive a royalty on each product commercialized under the agreement consisting of a percentage of the net sales of such product ranging from mid-single digits up to low double-digit percent. Unless terminated earlier in accordance with its terms, the Intrexon Partnership continues in effect until the later of (i) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration, and (ii) expiration of the last to expire royalty term for a product developed under the collaboration. The royalty term of a product developed under the Intrexon Partnership, with respect to each country, consists of the period equal to the longer of: (a) the duration of any valid claim of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers the product in such country or (b) ten years following the date of the first commercial sale of such product in such country. Intrexon may terminate the agreement prior to expiration for any reason on a product-by-product basis upon 90 days prior written notice to us. Upon any such termination, the license granted to Intrexon (in total or with respect to the terminated product, as applicable) will terminate. Intrexon’s chief executive officer, chairman of its board of directors and major shareholder is also a member of our board of directors.

We identified the deliverables at the inception of the ViroPharma and Intrexon agreements which are the license, research and development services and API supply. We have determined that the license, research and development services and API supply individually represent separate units of accounting, because each deliverable has standalone value. The estimated selling prices for these units of accounting was determined based on market conditions, the terms of comparable collaborative arrangements for similar technology in the pharmaceutical and biotech industry and entity-specific factors such as the terms of our previous collaborative agreements, our pricing practices and pricing objectives and the nature of the research and development services to be performed for the partners. The arrangement consideration was allocated to the deliverables based on the relative selling price method.

The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable other than for the potential effects of refund rights, concessions or performance bonuses. The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, we excluded from the allocable arrangement consideration the milestone payments, annual exclusivity fees and royalties regardless of the probability of receipt because such payments are not considered fixed or determinable. Such payments will be evaluated separately as the related contingencies are resolved. Based on the results of our analysis, we allocated the $9 million upfront license fee to the license deliverable under the ViroPharma arrangement and the $9 million upfront license fee to the license deliverable under the Intrexon arrangement. We determined that the upfront payment was earned upon the granting of the worldwide, exclusive right to our technology to the collaborator in both the ViroPharma Partnership and Intrexon Partnership. As a result, we recognized the $9 million upfront license fee received under the ViroPharma Partnership and the $9 million upfront license fee received under the Intrexon Partnership as revenues under collaborative agreements upon receipt of the upfront license fees.

We will recognize the annual exclusivity fees as revenues under collaborative agreements when they are due and payable on each anniversary of the effective date and such amounts will be included in the allocable arrangement consideration and recognized based on the relative selling price allocation. We will recognize amounts allocated to research and development services as revenues under collaborative agreements as the related services are performed. We will recognize amounts allocated to the sales of API as revenues under collaborative agreements when such API has met all required specifications by the partners and the related title and risk of loss and damages have passed to the partners. We cannot predict the timing of delivery of research and development services and API as they are at the partners’ requests.

We are eligible to receive additional cash payments upon the achievement by the partners of specified development, regulatory and sales-based milestones. We have determined that each of the development and regulatory milestones is substantive; therefore, we expect to recognize such development and regulatory milestone payments as revenues under collaborative agreements upon achievement in accordance with the Milestone Method. In addition, we have determined that the sales-based milestone payment is similar to a royalty payment and is not considered a milestone payment under the Milestone

Method of revenue recognition; therefore, we will recognize the sales-based milestone payment as revenue upon achievement of the milestone because we have no future performance obligations associated with the milestone. There were no milestone payments recognized as revenue under the collaborative agreements under these partnerships for the three months ended March 31, 2012 and 2011.”

***

In connection with the Company’s response to the Staff’s comments, the Company acknowledges that:

•

The Company is responsible for the adequacy and accuracy of the disclosure in the Company’s SEC filings;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: request for more time, Aug 8, 2012, closing letter, 2012-10-16

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 19 letters filed since 2012-08-06. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.